Overall Technical outlook

Price Summary

On 2025-06-12, Glenmark Pharmaceuticals Limited's stock opened at 1639.9, reached a high of 1662.3, dropped to a low of 1632.6, and closed down -0.02% at 1639.6, with a trading volume of 858824 shares.
In the 52-week period, the stock's peak price is 1818.15, and the lowest price recorded is 1213.35.
The future price of GLENMARK is projected to range from 1300.0 to 2011.0, with an average expected price of 1678.4166, according to 12 analysts.

Technicals


Aroon: The continuation of Aroon's bullish trend, with Aroon Up remaining at 100, signals strong momentum. However, to fully assess the trend's future potential, it should be analyzed in conjunction with other technical indicators.
GLENMARK aroon 6a4e02
Aroon chart for Glenmark Pharmaceuticals Limited


Bol. Bands: The BOLL BANDS is showing a neutral reading, with no clear direction indicated for upward or downward movement. This neutral position suggests a possible period of consolidation.
GLENMARK bbands 6a4e02
Bolinger Bands chart for Glenmark Pharmaceuticals Limited


Parabolic SAR: The PSAR maintains its bullish stance, setting a significant support level that could help sustain the market's upward movement. This strong support suggests that Glenmark Pharmaceuticals Limited is likely to continue trending higher, providing investors with confidence in the ongoing bullish momentum.
GLENMARK psar 6a4e02
Parabolic Stop and Reverse chart for Glenmark Pharmaceuticals Limited


Stochastic: The stochastic indicator reflects the K-line falling below the D-line, though it remains above 80, hinting at the possible start of a bearish price move. This suggests that the market may be losing its recent strength, with a potential decline ahead. Traders should be on the lookout for further evidence of a bearish trend for Glenmark Pharmaceuticals Limited.
GLENMARK stoch 6a4e02
Stochastic chart for Glenmark Pharmaceuticals Limited


Tripple Moving Agerage: The 20, 50, and 100 moving averages are aligned in a bearish formation, suggesting a downtrend. However, the slopes of the 20 and 50 SMAs are beginning to waver, indicating that the bearish momentum may be losing strength. This weakening could signal a potential shift towards bullish price action, as the market's current downward trajectory shows signs of faltering and a possible reversal may be near for GLENMARK.
GLENMARK trippleSMA 6a4e02
Tripple SMA chart for Glenmark Pharmaceuticals Limited


To make the most of a company's technical analysis, it's important to start with an understanding of its fundamentals. These include profitability, cash flow, and competitive positioning. Additionally, the industry in which the company operates plays a critical role, as trends and external factors can influence its market performance. By considering both the company's internal fundamentals and the external industry environment, more meaningful and accurate conclusions can be drawn from the technical data.